Clinical study of capecitabine combined chemotherapy regimen in treatment of advanced colorectal cancer in senile patients
- VernacularTitle:卡培他滨联合方案治疗老年晚期结直肠癌的临床研究
- Author:
Liang GAO
;
Yongxiang WANG
;
Liqin LU
;
Tongwei ZHAO
- Publication Type:Journal Article
- Keywords:
Vaderly;
Cobrectal neoplasms;
Oxaliplatin;
Capecitabine
- From:
Chinese Journal of Postgraduates of Medicine
2008;31(24):20-23
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evalume the efficacy and side effect of capecitabine combined chemotherapy regimen in treatment of advanced cohrectal cancer in senile patients.Methods Seventy-seven cases senile patients with advanced colorectal cancer were randomly divided in two groups.capecitabine combination group (36 cases) received oxaliplatin (L-OHP)+ eapecitabine regimen, OLF group (41 cases) received L-OHP+ FU/CF regimen. The efficacy and side effect were observed and compared between two groups.Results eapecitabine combination group:the cfficiency rate was 41.67%,the tumor control rate was 77.78%.meso-tumor to progression was 7.9 months.OLF group:the efficiency rate was 39.02%,the tumor control rate was 75.61%,meso-tumor to progression was 7.2 months.The effectiveness in two groups had no significant difference (P＞005).There was no serious chemotherapy related side effect in two groups.The rates of marrow inhibition,nausea,vomiting,diarrhea,alopecia,rash,the lesion of liver and renal function and peripheral neuritis were similar in two groups.The rate of hand-foot syndrome was apparently higher in capecitabine combination group compared with OLF group (P＜0.05).Conclusions For senile advanced colorectal cancer patienrs,the treatment efficiency is similar between capecitabiae combination regimen and OLF regimen,the side effect is all tolerated in two regimens.capecitabine combination regimen is oral adminisuered and decurates hospitnlization time and improved the life quality of senile patients.capecitabine combination regimen is a suitable fast-line regimen for senile advanced colorectal cancer pafients.
